206 related articles for article (PubMed ID: 16456551)
1. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.
García-Hernández E; González-Sánchez JL; Andrade-Manzano A; Contreras ML; Padilla S; Guzmán CC; Jiménez R; Reyes L; Morosoli G; Verde ML; Rosales R
Cancer Gene Ther; 2006 Jun; 13(6):592-7. PubMed ID: 16456551
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.
Corona Gutierrez CM; Tinoco A; Navarro T; Contreras ML; Cortes RR; Calzado P; Reyes L; Posternak R; Morosoli G; Verde ML; Rosales R
Hum Gene Ther; 2004 May; 15(5):421-31. PubMed ID: 15144573
[TBL] [Abstract][Full Text] [Related]
3. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study.
Albarran Y Carvajal A; de la Garza A; Cruz Quiroz BJ; Vazquez Zea E; Díaz Estrada I; Mendez Fuentez E; López Contreras M; Andrade-Manzano A; Padilla S; Varela AR; Rosales R
BioDrugs; 2007; 21(1):47-59. PubMed ID: 17263589
[TBL] [Abstract][Full Text] [Related]
4. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.
Rosales R; López-Contreras M; Rosales C; Magallanes-Molina JR; Gonzalez-Vergara R; Arroyo-Cazarez JM; Ricardez-Arenas A; Del Follo-Valencia A; Padilla-Arriaga S; Guerrero MV; Pirez MA; Arellano-Fiore C; Villarreal F
Hum Gene Ther; 2014 Dec; 25(12):1035-49. PubMed ID: 25275724
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials.
Tang J; Li M; Zhao C; Shen D; Liu L; Zhang X; Wei L
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215833
[TBL] [Abstract][Full Text] [Related]
6. Cold-knife conization versus photodynamic therapy with topical 5-aminolevulinic acid (5-ALA) in cervical intraepithelial neoplasia (CIN) II with associated human papillomavirus infection: a comparison of preliminary results.
Bodner K; Bodner-Adler B; Wierrani F; Kubin A; Szölts-Szölts J; Spängler B; Grünberger W
Anticancer Res; 2003; 23(2C):1785-8. PubMed ID: 12820459
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
8. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
[TBL] [Abstract][Full Text] [Related]
9. Candidate HPV genotypes not included in the 9-valent vaccine for prevention of CIN 2-3.
Gonzalez-Bosquet E; Gibert M; Serra M; Hernandez-Saborit A; Gonzalez-Fernandez A
Int J Gynecol Cancer; 2020 Jul; 30(7):954-958. PubMed ID: 32467333
[TBL] [Abstract][Full Text] [Related]
10. Expression of p16
Badiga S; Chambers MM; Huh W; Eltoum IA; Piyathilake CJ
Cancer; 2016 Dec; 122(23):3615-3623. PubMed ID: 27479745
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.
Roman LD; Wilczynski S; Muderspach LI; Burnett AF; O'Meara A; Brinkman JA; Kast WM; Facio G; Felix JC; Aldana M; Weber JS
Gynecol Oncol; 2007 Sep; 106(3):558-66. PubMed ID: 17631950
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
[TBL] [Abstract][Full Text] [Related]
14. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization.
Costa S; De Simone P; Venturoli S; Cricca M; Zerbini ML; Musiani M; Terzano P; Santini D; Cristiani P; Syrjänen S; Syrjänen K
Gynecol Oncol; 2003 Aug; 90(2):358-65. PubMed ID: 12893200
[TBL] [Abstract][Full Text] [Related]
15. Effect of High-Risk Human Papillomavirus but Normal Cytology at Test of Cure on Achieving Colposcopy Standards.
Kalampokas E; Wilson J; Gurumurthy M; Cruickshank ME
J Low Genit Tract Dis; 2018 Apr; 22(2):110-114. PubMed ID: 29474235
[TBL] [Abstract][Full Text] [Related]
16. Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women.
Hernández-Hernández DM; Ornelas-Bernal L; Guido-Jiménez M; Apresa-Garcia T; Alvarado-Cabrero I; Salcedo-Vargas M; Mohar-Betancourt A; Garcia-Carranca A
Gynecol Oncol; 2003 Aug; 90(2):310-7. PubMed ID: 12893192
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial.
van de Laar RLO; Hofhuis W; Duijnhoven RG; Polinder S; Melchers WJG; van Kemenade FJ; Bekkers RLM; Van Beekhuizen HJ
BMC Cancer; 2020 Jun; 20(1):539. PubMed ID: 32517663
[TBL] [Abstract][Full Text] [Related]
18. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence?
Nagai Y; Maehama T; Asato T; Kanazawa K
Gynecol Oncol; 2000 Nov; 79(2):294-9. PubMed ID: 11063660
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears.
Derchain SF; Rabelo-Santos SH; Sarian LO; Zeferino LC; de Oliveira Zambeli ER; do Amaral Westin MC; de Angelo Andrade LA; Syrjänen KJ
Gynecol Oncol; 2004 Dec; 95(3):618-23. PubMed ID: 15581973
[TBL] [Abstract][Full Text] [Related]
20. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
